Form 4: Nuvalent CEO James Porter Executes Stock Transactions Under 10b5-1 Plan

Nuvalent's CEO, James Porter, executed multiple stock transactions, including option exercises and sales, under a pre-arranged 10b5-1 trading plan.

Summary

• James Porter, the President and CEO of Nuvalent, Inc., engaged in several transactions involving the company's Class A Common Stock on January 15, 2025.
• These transactions included the exercise of stock options to acquire 27,000 shares at $27.85 per share and the sale of 26,999 shares at weighted average prices ranging from $74.94 to $77.28.
• The sales were executed in multiple transactions at varying prices within the specified ranges.
• These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on April 2, 2024.
• Following these transactions, Mr. Porter directly owns 249,062 shares of Class A Common Stock and 312,780 stock options.

Sentiment

Score: 5

Explanation: The document reflects routine executive stock transactions under a pre-arranged plan, which is neither particularly positive nor negative. The sentiment is neutral.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, which is a common practice for executives to avoid insider trading accusations.
• The exercise of stock options indicates the CEO's belief in the company's long-term prospects.

Negatives

• The sale of a significant number of shares by the CEO could be interpreted negatively by some investors, although it is part of a pre-planned strategy.

Risks

• The market may react negatively to the CEO selling shares, even if it is part of a pre-planned trading plan.
• Fluctuations in the stock price could impact the value of the remaining shares and options held by the CEO.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies, and the use of 10b5-1 plans is a standard practice to manage insider trading risks. This filing is a routine disclosure of such activity.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan is a common practice among executives at publicly traded companies, including those in the biotechnology sector like Nuvalent.
• Similar filings are regularly made by executives at companies like Amgen (AMGN), Gilead Sciences (GILD), and Regeneron Pharmaceuticals (REGN) when they execute stock transactions.
• The price ranges at which the shares were sold are within the typical trading range for a company like Nuvalent, which is a clinical-stage biopharmaceutical company.

Stakeholder Impact

• Shareholders may react to the CEO's stock sales, although the transactions are part of a pre-planned strategy.
• The transactions do not directly impact employees, customers, suppliers, or creditors.

Key Dates

Keywords

stock transactions, Rule 10b5-1, insider trading, stock options, executive compensation, Class A Common Stock, Nuvalent, NUVL